<unk>  is an antineoplastic agent that is FDA approved for the treatment of advanced renal cell carcinoma.   Common adverse reactions include edema, rash, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypophosphatemia, inflammatory disease of mucous membrane, loss of appetite, nausea, decreased hemoglobin, decreased lymphocyte count, decreased platelet count, leukopenia, neutropenia, alkaline phosphatase raised, AST/SGOT level raised, asthenia, serum creatinine raised.
Temsirolimus
Tacrolimus 
Sirolimus
Pimecrolimus
Ruxolitinib
Ceritinib
Rituximab
Pembrolizumab